The American Society of Clinical Oncology (ASCO) have updated their guideline on metastatic pancreatic cancer, Metastatic Pancreatic Cancer: ASCO Guideline Update.
The purpose of the update was to incorporate new evidence relevant to Clinical Question 3 from previous versions of the guideline: What is the appropriate therapy for patients with metastatic pancreatic cancer who experience either disease progression or intolerable toxicity with prior regimens? To answer this question, the society convened an expert panel and conducted a systematic review to provide updated recommendations on second-line therapy for metastatic pancreatic cancer.
The updated guideline now takes into account one randomised controlled trial of olaparib versus placebo, one report on phase I and II studies of larotrectinib, and one report on phase I and II studies of entrectinib. New or updated recommendations are included on germline and somatic testing for microsatellite instability high/mismatch repair deficiency, BRCA mutations, and TRK alterations in treatment-eligible patients. The new recommendations are intended to help select patients for recommended therapies, including pembrolizumab, olaparib, larotrectinib, or entrectinib, or potential clinical trials.